Next Article in Journal
Iron Therapeutics in Women’s Health: Past, Present, and Future
Next Article in Special Issue
A Safe GDNF and GDNF/BDNF Controlled Delivery System Improves Migration in Human Retinal Pigment Epithelial Cells and Survival in Retinal Ganglion Cells: Potential Usefulness in Degenerative Retinal Pathologies
Previous Article in Journal
Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules
Previous Article in Special Issue
Nanotechnology for the Treatment of Allergic Conjunctival Diseases
Review

A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications

2nd Department of Ophthalmology, Aristotle University of Thessaloniki, 564 29 Thessaloniki, Greece
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(12), 448; https://doi.org/10.3390/ph13120448
Received: 14 October 2020 / Revised: 4 December 2020 / Accepted: 5 December 2020 / Published: 8 December 2020
(This article belongs to the Special Issue Advances in Ocular Pharmacology)
Cataract surgery is the commonest ophthalmic surgery worldwide. The replacement of the diseased lens with a synthetic one (intraocular lens—IOL) remains the treatment of choice, despite its potential complications that include infection, inflammation and posterior capsule opacification. The potential for drug delivery via the IOL has been researched extensively over a period of twenty-five years, yet there is very limited progress in transferring the findings from research to everyday practice. The objective of this review is to assess the progress made in the field of IOL lens modifications and drug delivery systems over the past five years. Thirty-six studies that were conducted during the past five years were identified and deemed suitable for inclusion. They were grouped in three broad categories, studies that described new methods for loading a drug onto the IOL, assessment of the effects of drugs that were loaded to the IOL and studies that assessed the effects of non-pharmaceutical modifications of IOLs. While considerable progress is continually being made with regard to methods and materials, there is still little capitalization upon these research studies, with no commercially available IOL-based drug delivery system being available. Close cooperation between researchers in basic sciences (chemistry, physics, materials science and pharmacy), clinical researchers, IOL manufacturers and the pharmaceutical industry is an important prerequisite for further development. View Full-Text
Keywords: intraocular lens; cataract; drug delivery intraocular lens; cataract; drug delivery
Show Figures

Figure 1

MDPI and ACS Style

Mylona, I.; Tsinopoulos, I. A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications. Pharmaceuticals 2020, 13, 448. https://doi.org/10.3390/ph13120448

AMA Style

Mylona I, Tsinopoulos I. A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications. Pharmaceuticals. 2020; 13(12):448. https://doi.org/10.3390/ph13120448

Chicago/Turabian Style

Mylona, Ioanna, and Ioannis Tsinopoulos. 2020. "A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications" Pharmaceuticals 13, no. 12: 448. https://doi.org/10.3390/ph13120448

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop